Report overview
Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin.?The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system.?Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes.?Diabetes is also called hyperglycemia or raised blood sugar.?Insulin is a hormone that regulates the blood sugar level in body.?Continuous increase in blood sugar leads to diabetes.?Uncontrollable diabetes can damage the nervous system and other body systems.?Diabetes is of two types: type 1 and type 2.?Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas.?In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy.?Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes.?It commonly occurs in childhood or adolescence.?Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin.?As a consequence, sugar builds up in the blood instead of being used as energy.?About 90% of people with diabetes have type 2 diabetes.
This report aims to provide a comprehensive presentation of the global market for Oral Anti-diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-diabetes Drugs. This report contains market size and forecasts of Oral Anti-diabetes Drugs in global, including the following market information:
Global Oral Anti-diabetes Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Oral Anti-diabetes Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
by Type Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oral Anti-diabetes Drugs include Sanofi, Eli Lilly, AstraZeneca plc, Astellas Pharma Inc, Johnson & Johnson (Janssen Pharmaceuticals), Boehringer Ingelheim, Merck, Takeda and Bristol Myers Squibb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Anti-diabetes Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Anti-diabetes Drugs Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Oral Anti-diabetes Drugs Market Segment Percentages, by Type, 2022 (%)
by Type
Liquid
Capsule
Tablet
by Drug Class
Sulfonylureas
Meglitinides
Biguanides
Others
Global Oral Anti-diabetes Drugs Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Oral Anti-diabetes Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oral Anti-diabetes Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Oral Anti-diabetes Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Anti-diabetes Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Oral Anti-diabetes Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy?s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oral Anti-diabetes Drugs, market overview.
Chapter 2: Global Oral Anti-diabetes Drugs market size in revenue.
Chapter 3: Detailed analysis of Oral Anti-diabetes Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oral Anti-diabetes Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
